[Tolvaptan in autosomal dominant polycystic kidney disease]

Mengarelli C, Garcia Marti S, Alfie V, Argento F, Klappenbach R, Ciappon A, Bardach A, Augustovski F, Alcaraz A, Pichon Riviere A
Record ID 32018002314
Original Title: Tolvaptan en poliquistosis renal autosómica dominante
Authors' recomendations: Moderate-quality evidence suggests that the use of tolvaptan (vasopressin antagonist) in adult patients with autosomal dominant polycystic kidney disease with rapid progression of kidney growth might delay this growth associated with cysts and subsequent kidney function worsening. However, most of the patients receiving the drug experience common side effects, such as aquaresis (increase in water clearance), polyuria, nicturia, thirst, polydipsia, dry mouth, diarrhea and fatigue, and other less common ones, such as hepatotoxicity.
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Polycystic Kidney Diseases
  • Polycystic Kidney, Autosomal Dominant
  • Tolvaptan
  • Antidiuretic Hormone Receptor Antagonists
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.